Anti-Rheumatic Drugs - Iran

Iran

The projected revenue for the Anti-Rheumatic Drugs market in Iran is expected to reach US$217.10m in 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2028) of -0.07%, which will lead to a market volume of US$216.50m by 2028.
In comparison to other countries worldwide, United States is projected to generate the highest revenue in the Anti-Rheumatic Drugs market, with US$37,550.00m in 2024.
Iran's pharmaceutical market is experiencing a growing demand for anti-rheumatic drugs as the country's aging population continues to increase.

Key regions: France, Italy, Brazil, China, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Iran has been on a steady rise in recent years.

Customer preferences: Iran has a high prevalence of rheumatoid arthritis, which is the primary driver of the Anti-Rheumatic Drugs market in the country. Patients suffering from the disease prefer Anti-Rheumatic Drugs over other treatments as it provides long-term relief from pain and inflammation.

Trends in the market: The Anti-Rheumatic Drugs market in Iran has witnessed a shift towards biologic drugs due to their efficacy and safety. Biologic drugs have a higher cost, but patients are willing to pay for the benefits they offer. The market has also seen an increase in the number of generic drugs being introduced, which has led to increased competition and lower prices.

Local special circumstances: Iran has a large aging population, which is a significant factor driving the demand for Anti-Rheumatic Drugs. The country also has a high prevalence of rheumatoid arthritis, which is the primary driver of the market. The government's efforts to improve healthcare infrastructure and provide better access to healthcare services have also contributed to the growth of the market.

Underlying macroeconomic factors: The economic sanctions imposed on Iran have had a significant impact on the Anti-Rheumatic Drugs market. The sanctions have limited the country's ability to import raw materials and finished products, leading to a shortage of drugs in the market. The devaluation of the Iranian currency has also made it difficult for patients to afford expensive drugs, leading to a shift towards generic drugs. However, the government's efforts to improve the healthcare sector and provide better access to healthcare services have helped to mitigate the impact of the sanctions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.